Anogen is the leader among biopharmaceutical product manufacturers. Our mission is dedicated to supply the best quality of antibodies and ELISA Kits worldwide.
🔬 Anti-IL-8 antibodies continue to emerge as promising therapeutic candidates across oncology and inflammatory diseases.
Reference:
BMS-986253 / HuMax-IL8 Phase I trial (PubMed), https://t.co/WqVQ5eV3p5
#Anogen#IL8#Immunology#AntibodyTherapy#CancerResearch#Endometriosis
🧠 Vitamin D May Play a Bigger Role in Brain Health Than We Thought Recent research continues to highlight the connection between vitamin D deficiency and increased risk of cognitive decline, dementia, and Alzheimer’s disease.
🔗 Read more: https://t.co/YQwjTq0P1q
#Anogen
A recent publication from Tiziana Life Sciences highlights the potential of intranasal anti-CD3 therapy (foralumab) in modulating immune responses.
🔗 Read more: https://t.co/DjLuwXXmXo
#Immunotherapy#Neuroinflammation#Cytokines#CAR-T #Biotech#Anogen
Recent data from Tiziana Life Sciences highlights the potential of nasal anti-CD3 therapy (foralumab) in modulating immune responses linked to neuroinflammation and cognitive decline.
📌 Read the full article: https://t.co/l3UxeYAdDT
#Anogen
🧠 Tau protein plays a key role in neuron stability — but its abnormal buildup is strongly linked to Alzheimer’s disease.
At Anogen, we support studies with recombinant proteins & antibodies for key biomarkers.#Alzheimers#TauProtein#Neuroscience
We’re proud to share that our Mouse Interleukin-1β (IL-1β) ELISA Kit (MEC1010) played a key role in a groundbreaking study published in Nature Communications.
Read the full article here: https://t.co/1dh2u6qeUC
https://t.co/s28cbpJ1lD
#InflammationResearch#Anogen
A new study from Washington University School of Medicine reports encouraging evidence that anti-amyloid treatment given before symptoms appear may help delay or prevent Alzheimer’s dementia.
Read more:
https://t.co/iJjHLU6hBy
#Alzheimers#Neuroscience#Anogen
A recent article in Biomedical Research and Therapy explores the role of amyloid-β plaques and tau neurofibrillary tangles in Alzheimer’s disease and the therapeutic strategies targeting these pathologies.
Read the article:
https://t.co/MueI7ddiGE
#AlzheimersDisease#Anogen
A study published in Biology Direct reveals how hypoxia influences microglia and promotes glioma growth through inflammatory cytokine secretion
https://t.co/7kBZcQmosY
New research has created a detailed molecular atlas of tau — pinpointing 145 unique modifications and 195 cleavage sites across tauopathies like Alzheimer’s.
Read the full article: https://t.co/qhjTbMdJWZ
#Anogen#Neurology#Neurodegeneration#AlzheimersResearch
🧠 Cell highlights how Alzheimer’s therapy is moving beyond amyloid alone—embracing tau targeting, neuroinflammation, and multi-modal strategies to better address disease complexity and drive future breakthroughs. Read the full article: https://t.co/iOldCjrOnP
#Alzheimers#Anogen
The investigational anti-tau agent VY7523 showed a favorable safety and tolerability profile in an early Alzheimer’s trial. https://t.co/gptsbWVooq
#Alzheimers#Tau#Neuroscience#ClinicalResearch
Anti-amyloid monoclonal antibodies—like lecanemab and donanemab, are changing the landscape of Alzheimer’s disease care by targeting amyloid-β plaques, a core driver of disease.
Read the full article here: https://t.co/yaiBO0m4G8
#AlzheimersResearch#Anogen